



Financial Tear Sheet

Corporate Profile

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics. The company's lead FDA approved commercial product, NUZYRA™ (omadacycline) is a once-daily intravenous and oral antibiotic for the treatment of adult patients with CABP and ABSSSI caused by susceptible pathogens. Paratek is also studying NUZYRA™ for the treatment of urinary tract infections (UTI).

Paratek has submitted a marketing authorization application for omadacycline in the European Union. Paratek has entered into a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Under a research agreement with the U.S. Department of Defense, omadacycline also is being studied against pathogenic agents causing infectious diseases of public health and biodefense importance, including plague and anthrax.

Paratek's second FDA approved commercial product, SEYSARA™ (sarecycline), is marketed by Almirall, LLC in the U.S. as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris. Paratek retains development and commercialization rights to sarecycline in the rest of the world.

Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

Stock Information

PRTK (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$6.25
Change (%)	▼ 0.15 (2.34%)
Volume	470,088
52 Week Low	\$4.50
Market Cap	\$202,599,856
Rolling EPS	-3.57
PE Ratio	N/A
Shares Outstanding	32,415,977



Data as of 03/18/19 4:00 p.m. ET

Recent Paratek Pharmaceuticals News & Events

03/18/19 - 8:01 a.m.

Paratek Pharmaceuticals Announces
Management Change

There are currently no events scheduled.

03/01/19 - 4:30 p.m.

Paratek Announces Inducement Grants
under NASDAQ Listing Rule 5635(c)(4)

03/01/19 - 8:00 a.m.

Paratek Pharmaceuticals to Present at the
Cowen and Company 39th Annual Health
Care Conference

SEC Filings

Filing Date	Form
03/18/19	CT ORDER
03/18/19	8-K
03/06/19	S-8
03/06/19	10-K

Management

Michael F. Bigham	Chief Executive Officer and Chairman of the Board
Evan Loh, M.D.	President, Chief Operating Officer and Chief Medical Officer
Douglas W. Pagán	Chief Financial Officer
Adam Woodrow	Chief Commercial Officer
William Haskel	General Counsel and Corporate Secretary
Randy Brenner	Senior Vice President - Regulatory, Quality and Technical Operations
Evan Tzanis	Chief Development Officer
Jason Burdette	Vice President - Technical Operations

Jeanne Jew	Senior Vice President - Business Development
Raj Padmanabhan	Vice President - Information Technology
Susan Perkins, J.D.	Vice President - Intellectual Property
Christine R. Coyne, MBA	Vice President - Marketing
Sarah Higgins	Vice President - Controller
Paul McGovern, M.D.	Vice President - Clinical and Medical Affairs
Steve Sandor, MBA, J.D.	Vice President - Market Access and Trade
Judith N. Steenbergen, PhD	Vice President, Medical Strategy and Communications

Data provided by Nasdaq. Minimum 15 minutes delayed.